^
    2d
    Solitary adrenal metastatic adenocarcinoma one year after radical gastrectomy for gastric cancer: a case report. (PubMed, Front Med (Lausanne))
    The patient completed six cycles of adjuvant chemotherapy with tegafur-gimeracil-oteracil (S-1) plus oxaliplatin, and routine follow-up examinations showed no evidence of recurrence...The patient was treated with SOX chemotherapy combined with the PD-1 inhibitor tislelizumab...This case highlights the importance of vigilance for rare metastatic sites, such as the adrenal gland, in patients with advanced gastric cancer even after standardized postoperative surveillance. Systemic chemotherapy combined with immunotherapy may represent an effective treatment strategy for selected patients with metastatic gastric cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CA 19-9 (Cancer antigen 19-9)
    |
    Tevimbra (tislelizumab-jsgr) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    5d
    Pembrolizumab plus chemotherapy following lack of response to nivolumab-based therapy in MSI-High/dMMR advanced gastric cancer: a case report. (PubMed, Int Cancer Conf J)
    He subsequently received ramucirumab-based therapy, paclitaxel, and irinotecan...Pembrolizumab combined with capecitabine and oxaliplatin (CAPOX) was initiated as fifth-line therapy, resulting in notable regression of hepatic and nodal metastases. This case underscores the clinical importance of early MSI/MMR and genomic testing and suggests that re-administration of ICI plus chemotherapy may be a therapeutic option for selected patients with advanced gastric cancer who initially show limited response to ICI-based therapy.
    Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • MSI-H • dMMR
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • PMS2 (PMS1 protein homolog 2)
    |
    MSI-H/dMMR • HER-2 negative
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • paclitaxel • capecitabine • Cyramza (ramucirumab) • oxaliplatin • irinotecan • Teysuno (gimeracil/oteracil/tegafur)
    6d
    Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy and pembrolizumab (2025-524229-41-00)
    P2/3, N=1000, Not yet recruiting, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 expression
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • capecitabine • Teysuno (gimeracil/oteracil/tegafur)
    7d
    Metastatic Breast Cancer Presenting as an Organizing Pneumonia Pattern on Chest CT: A Case Report. (PubMed, Cureus)
    The patient had been receiving fulvestrant for known pulmonary metastasis diagnosed 14 years prior...Treatment with S-1 resulted in radiological improvement at four months. This case adds to the limited literature documenting OP-mimicking pulmonary metastasis from breast cancer and highlights the importance of maintaining a high index of suspicion and pursuing tissue diagnosis in patients with a history of breast cancer who present with new pulmonary infiltrates.
    Journal
    |
    ER (Estrogen receptor) • GATA3 (GATA binding protein 3)
    |
    fulvestrant • Teysuno (gimeracil/oteracil/tegafur)
    7d
    Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases (clinicaltrials.gov)
    P2, N=50, Recruiting, Ruijin Hospital
    New P2 trial
    |
    Tyvyt (sintilimab) • Tevimbra (tislelizumab-jsgr) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    13d
    Gemcitabine/nab-paclitaxel plus S-1 combination compared with gemcitabine/nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: a retrospective study. (PubMed, Ther Adv Med Oncol)
    No treatment-related mortality was found. The S-1 could be combined with GA as another potential triplet combination treatment option for advanced PDAC.
    Retrospective data • Journal
    |
    FoundationOne® CDx
    |
    gemcitabine • albumin-bound paclitaxel • Teysuno (gimeracil/oteracil/tegafur)
    13d
    TOURMALINE: Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (clinicaltrials.gov)
    P3, N=142, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2026 --> Sep 2026
    Trial completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    13d
    A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=276, Recruiting, Fudan University
    New P2 trial • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    19d
    IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New P2 trial
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)
    24d
    Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer. (PubMed, Target Oncol)
    Copy number-based oncogene dominance may suggest tumor dependence and response to HER2-targeted therapy, highlighting a potential novel biomarker in HER2-positive gastric cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • FGFR2 (Fibroblast growth factor receptor 2) • CCNE1 (Cyclin E1)
    |
    HER-2 positive • HER-2 amplification • EGFR positive
    |
    Herceptin (trastuzumab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    26d
    Neoadjuvant PD-1 inhibitor combined with FLOT versus SOX for locally advanced gastric cancer: a retrospective cohort study. (PubMed, Front Immunol)
    We compared neoadjuvant PD-1 inhibitor plus S-1+oxaliplatin (SOX) versus PD-1 inhibitor plus 5-FU+oxaliplatin+Docetaxel+Leucovorin (FLOT) in a real-world cohort...Neoadjuvant PD-1 inhibitor plus SOX and plus FLOT yielded comparable response rates, survival outcomes, and safety profiles in patients with resectable LAGC/EGJ adenocarcinoma. PD-1+SOX was associated with less operative burden, and MPR remained independently associated with OS and RFS, supporting its value for risk stratification and treatment optimization.
    Clinical • Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Teysuno (gimeracil/oteracil/tegafur)
    27d
    SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • retlirafusp alfa (SHR-1701)